Search Results
Oct 23, 2025, 06:01 ET NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025
Kadimastem has executed a technology transfer and clinical manufacturing agreement with Pluri Inc., a GMP-certified CDMO partner. The technology transfer, training, and product release certification have been successfully completed. Clinical manufacturing is expected to
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Oct 22, 2025, 12:00 ET SynbioTech Brings Taiwan's Biotech Excellence to the Global Stage with TWK10® for Muscle Performance and Healthy Aging
company specializing in probiotics, postbiotics, and microbiome-based health solutions. With over 25 years of R&D experience and a fully integrated CDMO platform, the company partners with more than 600 brands across 35 countries to deliver "From Strain to Solution" innovations that change lives with
More news about: SYNBIO TECH INC.
Oct 22, 2025, 09:03 ET REPROCELL USA Receives Funding from the Maryland Stem Cell Research Fund (MSCRF)
Grant Program, as a part of the July 2025 grant cycle. This grant will support the development of a Contract Development and Manufacturing Organization (CDMO) in Maryland. BELTSVILLE, Md., Oct.
More news about: REPROCELL USA
Oct 22, 2025, 06:00 ET Cambrex Unveils $120 Million Investment to Expand API Manufacturing and Strengthen U.S. Drug Supply Resilience
RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S. operations, addressing increased demand for API development and manufacturing, and accelerating
More news about: Cambrex
Oct 22, 2025, 06:00 ET Cambrex Unveils $120 Million Investment to Expand API Manufacturing and Strengthen U.S. Drug Supply Resilience
RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S. operations, addressing increased demand for API development and manufacturing, and accelerating
More news about: Cambrex
Oct 22, 2025, 06:00 ET Cambrex stellt 120-Millionen-Dollar-Investition zum Ausbau der API-Produktion und zur Stärkung der Widerstandsfähigkeit der US-Arzneimittelversorgung vor
22. Oktober 2025 /PRNewswire/ -- Cambrex, ein weltweit führendes Auftragsentwicklungs- und -herstellungsunternehmen (CDMO), gab heute eine Investition in Höhe von 120 Millionen US-Dollar bekannt, um seinen Betrieb in den USA zu erweitern, die steigende Nachfrage nach API-Entwicklung
More news about: Cambrex
Oct 22, 2025, 06:00 ET Cambrex Revela Investimento de $ 120 Milhões para Expandir a Fabricação de APIs e Fortalecer a Resilience do Fornecimento de Medicamentos nos EUA
22 de outubro de 2025 /PRNewswire/ -- A Cambrex, organização líder global de desenvolvimento e fabricação sob contrato (CDMO), anunciou hoje um investimento de $ 120 milhões para expandir suas operações nos EUA, atendendo ao aumento da demanda por desenvolvimento e fabricação
More news about: Cambrex
Oct 22, 2025, 06:00 ET Cambrex expandirá la fabricación de API y fortalecerá el suministro de medicamentos en EE. UU.
22 de octubre de 2025 /PRNewswire/ -- Cambrex, una organización líder mundial en desarrollo y fabricación por contrato (CDMO), anunció hoy una inversión de 120 millones de dólares para expandir sus operaciones en EE. UU., abordando la creciente demanda de desarrollo y fabricación
More news about: Cambrex
Oct 22, 2025, 06:00 ET Cambrex anuncia una inversión de $ 120 millones para expandir la fabricación de API y fortalecer la resiliencia del suministro de medicamentos de EE. UU
22 de octubre de 2025 /PRNewswire/ -- Cambrex, una organización líder mundial de desarrollo y fabricación por contrato (CDMO, por sus siglas en inglés), anunció hoy una inversión de $ 120 millones para expandir sus operaciones en EE. UU., abordando el aumento de la demanda
More news about: Cambrex
Oct 22, 2025, 06:00 ET Cambrex dévoile un investissement de 120 millions de dollars pour développer la fabrication d'IPA et renforcer la résilience de l'approvisionnement en médicaments aux États-Unis
22 octobre 2025 /PRNewswire/ -- Cambrex, une organisation mondiale de développement et de fabrication sous contrat (CDMO) de premier plan, a annoncé aujourd'hui un investissement de 120 millions de dollars pour étendre ses activités aux États-Unis, afin de répondre à la
More news about: Cambrex
Oct 21, 2025, 15:12 ET Kenox Pharmaceuticals Appoints Dr. Julianne Berry as Vice President of R&D and Manufacturing
worldwide. About Kenox Pharmaceuticals Inc.: Kenox Pharmaceuticals is a specialized CDMO focused exclusively on inhalation, intranasal, and ophthalmic therapies. With fully integrated R&D, fill-finish, and analytical testing capabilities,
More news about: Kenox Pharmaceuticals Inc.
Oct 21, 2025, 09:39 ET Alcami to Expand Laboratory Services Footprint at Durham, NC Facility to Meet Growing Demand in Biologics
Oct. 21, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading U.S.-based contract development and manufacturing organization (CDMO), is pleased to announce the expansion of its laboratory services at the Creekstone Drive facility in Durham, NC. This strategic investment reinforces
More news about: Alcami
Oct 21, 2025, 02:00 ET Codis Appoints Steven Facer as Senior VP Sales and Marketing to Support the Haverhill, UK Facility
ST. LOUIS, Oct. 21, 2025 /PRNewswire/ -- Codis, a global CDMO specializing in commercial spray drying, amorphous solid dispersions (ASD), and particle engineering technologies, has appointed Steven Facer as the
More news about: Codis
Oct 21, 2025, 02:00 ET Codis Appoints Steven Facer as Senior VP Sales and Marketing to Support the Haverhill, UK Facility
ST. LOUIS, Oct. 21, 2025 /PRNewswire/ -- Codis, a global CDMO specializing in commercial spray drying, amorphous solid dispersions (ASD), and particle engineering technologies, has appointed Steven Facer as the
More news about: Codis
Oct 17, 2025, 10:40 ET Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market is expected to generate a revenue of USD 6.48 Billion by 2032, Globally, at 8.2% CAGR: Verified Market Research®
biologic drug development. While high production costs and regulatory complexities pose challenges, advancements in aseptic processing and the rise of CDMO partnerships create lucrative opportunities. North America and Europe offer high-value, compliance-driven markets, whereas Asia-Pacific provides cost-efficient
More news about: Verified Market Research
Oct 17, 2025, 00:30 ET Dietary Fiber Gummies Market to Reach USD 13.44 billion by 2032, Growing At An 11.2% CAGR - Credence Research
Industries announced the acquisition of Island Abbey Nutritionals, a Canadian-based contract development and manufacturing organization (CDMO) specializing in supplement gummies and lozenges. The deal, valued at $20 million plus performance-based payments, is set to expand TopGum's manufacturing
More news about: Credence Research Inc.
Oct 16, 2025, 12:11 ET Codis Raises Growth Capital to Expand Commercial Manufacturing; Welcomes 1315 Capital
ST. LOUIS, Oct. 16, 2025 /PRNewswire/ -- Codis, a CDMO focused on commercial spray drying, amorphous solid dispersions (ASD), particle engineering, and finished-dose manufacturing, today announced a growth
More news about: Codis
Oct 16, 2025, 12:09 ET Codis Raises Growth Capital to Expand Commercial Manufacturing; Welcomes 1315 Capital
ST. LOUIS, Oct. 16, 2025 /PRNewswire/ -- Codis, a CDMO focused on commercial spray drying, amorphous solid dispersions (ASD), particle engineering, and finished-dose manufacturing, today announced a growth
More news about: Codis
Oct 15, 2025, 08:46 ET Quintara Biosciences Completes Acquisition of Laragen Sanger Sequencing Business, Strengthening Service Continuity and Strategic Expansion in Los Angeles
About Quintara Biosciences Quintara Biosciences is a leading genomics and molecular biology CRO/CDMO providing comprehensive sequencing and molecular services to the biotech and academic research community. With operations in Boston, MA; San Fransico,
More news about: Quintara Biosciences
Oct 15, 2025, 02:00 ET Safex Chemicals India Ltd. Receives Frost & Sullivan's 2025 Global Competitive Strategy Leadership Recognition for Excellence in Crop Protection Chemicals
facility, and rainwater conservation systems designed to minimize environmental impact. Safex's acquisition of a major UK-based CDMO facility has accelerated its global expansion, enabling access to new international markets and partnerships. This acquisition, coupled with the implementation
More news about: Frost & Sullivan
Oct 15, 2025, 02:00 ET Safex Chemicals India Ltd. Receives Frost & Sullivan's 2025 Global Competitive Strategy Leadership Recognition for Excellence in Crop Protection Chemicals
facility, and rainwater conservation systems designed to minimize environmental impact. Safex's acquisition of a major UK-based CDMO facility has accelerated its global expansion, enabling access to new international markets and partnerships. This acquisition, coupled with the implementation
More news about: Frost & Sullivan
Oct 14, 2025, 09:00 ET Quotient Sciences and Biorasi partner to accelerate early phase clinical trials to patient proof-of-concept
accelerating data-driven decision making. The venture also expands opportunities for adjacent services including comprehensive CDMO offerings such as pharmacy compounding, drug product manufacturing, data sciences, and regulatory support.
More news about: Quotient Sciences
Oct 14, 2025, 02:00 ET Codis Launches as Global CDMO for Commercial Spray Drying and Amorphous Solid Dispersions
New global CDMO combines commercial spray drying and particle engineering technologies under one brand. Codis formed through integration of Particle Dynamics
More news about: Codis
Oct 14, 2025, 02:00 ET Codis Launches as Global CDMO for Commercial Spray Drying and Amorphous Solid Dispersions
New global CDMO combines commercial spray drying and particle engineering technologies under one brand. Codis formed through integration of Particle Dynamics
More news about: Codis
Oct 13, 2025, 14:34 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY
third-party manufacturing vendor"—specifically, a third-party subcontractor of Unicycive's contract development and manufacturing organization ("CDMO")—"following an FDA inspection" and that, "given the identified deficiencies, any label discussions between the FDA and the Company are precluded."
More news about: Pomerantz LLP